

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	JANJIC <i>et al.</i>	}	EXAMINER:	VIVLEMORE, T. A.
SERIAL NO.:	10/606,159		ART UNIT:	1635
FILED:	JUNE 24, 2003		CONF. NO.	3567
TITLE:	PLATELET DERIVED GROWTH FACTOR (PDGF) NUCLEIC ACID LIGAND COMPLEXES			

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

## INFORMATION DISCLOSURE STATEMENT

Applicant calls the Examiner's attention to the patents and publications listed on the attached Form PTO-1449, copies of required documents enclosed, which may be material to examination of the above identified application.

TIME OF TRANSMITTAL

This Information Disclosure Statement is being filed under 37 CFR § 1.97(b). This Statement is filed within at least one of the following time periods:

- (a) within three months of the filing date of a national application (other than a CPA under 37 CFR § 1.53(d));
- (b) within three months of the date of entry of the national stage as set forth in 37 CFR § 1.491 in an international application;
- (c) before the mailing of a first Office Action of the merits; or
- (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR § 1.114.

No fee is believed to be due in this instance. However, the undersigned hereby authorizes the charging of any fees created by the filing of this document to Deposit Account No. 19-5117.

The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. This listed patents and publications are believed of interest herein and consideration and citation of as interest by Examiner is respectfully requested.

Respectfully submitted,

Date: April 5, 2007



Mary Breen Smith, #43,512  
Swanson & Bratschun, L.L.C.  
1745 Shea Center Drive, Suite 330  
Highlands Ranch, Colorado 80129  
Telephone: (303) 268-0066  
Facsimile: (303) 268-0065

<b>FORM PTO-1449</b> <b>U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</b>  List of Information Cited by Applicant Page 1 of 1	<b>ATTY. DOCKET NO.</b>		<b>SERIAL NO.</b>
	NEX66/D2		10/606,159
	<b>APPLICANT</b>		
	JANJIC		
	<b>FILING DATE</b>		<b>GROUP</b>
	JUNE 24, 2003		1635

U.S. PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB- CLS	FILE DATE
	AA						
	AB						

FOREIGN PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS	TRANS ?
	AC	WQ 96/34876	11/07/1996	PCT			
	AD						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
AE	Maresta (1994) Circulation <u>90</u> :2710-2715, Trapidil (Triazolopyrimidine), a Platelet-Derived Growth Factor Antagonist, Reduces Restenosis After Percutaneous Transluminal Coronary Angioplasty	
AF	Ohta (1997) Chest <u>111</u> :105S, Suppressive Effect of Antisense DNA of Platelet Derived Growth Factor on Murine Pulmonary Fibrosis with Silica Particles	
AG	Stull and Szoka (1995) Pharmaceutical Research <u>12</u> :465-483, Antigene, Ribozyme and Aptamer Nucleic Acid Drugs: Progress and Prospects	
AH	Veronese and Pasut (2005) DDT <u>10</u> :1451-1458, PEGylation, successful approach to drug delivery	
AI		
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

S:\Client\Folders\Gilead (formerly NeXstar)\Nex66\D2\UD8 05.doc